Literature DB >> 28746841

The antidepressant effect of melatonin and fluoxetine in diabetic rats is associated with a reduction of the oxidative stress in the prefrontal and hippocampal cortices.

Redouane Rebai1, Luc Jasmin2, Abdennacer Boudah3.   

Abstract

In the past few years possible mechanisms that link diabetes and depression have been found. One of these mechanisms is the increase in lipid peroxidation and decrease in antioxidant activity in the hippocampal and prefrontal cortices, which are brain areas involved in mood. The goal of the present study was to evaluate the effect of an antidepressant and of an antioxidant on behavior and oxidative activity in brains of diabetic rats. Rats rendered diabetic after a treatment with streptozotocin (STZ) (60mg/kg) were treated with fluoxetine (15mg/kg), melatonin (10mg/kg), or vehicle for 4 weeks. All animals were tested for signs of depression and anxiety using the elevated plus maze (EPM), open field test (OFT) and the forced swim test (FST). Four groups were compared: (1) normoglycemic, (2) hyperglycemic vehicle treated, and hyperglycemic (3) fluoxetine or (4) melatonin treated rats. On the last day of the study, blood samples were obtained to determine the levels of hemoglobin A1c (HbA1c). Also, brain samples were collected to measure the oxidative stress in the hippocampal and prefrontal cortices using the thiobarbituric acid reactive substances (TBARS) assay. The activity of the antioxidant enzymes catalase (CAT), glutathione peroxidase (GPx), and glutathione S-transferase (GST) were also measured on the brain samples. The results show that both fluoxetine and melatonin decrease the signs of depression and anxiety in all tests. Concomitantly, the levels of HbA1c were reduced in drug treated rats, and to a greater degree in the fluoxetine group. In the cerebral cortex of diabetic rats, TBARS was increased, while the activity of CAT, GPx and GST were decreased. Fluoxetine and melatonin treatments decreased TBARS in both cortices. In the prefrontal cortex, fluoxetine and melatonin restored the activity of CAT, while only melatonin improved the activity of GPx and GST. In the hippocampus, the activity of GPx alone was restored by melatonin, while fluoxetine had no effect. These results suggest that antidepressants and antioxidants can counter the mood and oxidative disorders associated with diabetes. While these effects could result from a decreased production of reactive oxygen species (ROS) remains to be established.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Depression; Diabetes mellitus; Enzymatic regulation; Fluoxetine; Melatonin; Oxidative stress

Mesh:

Substances:

Year:  2017        PMID: 28746841     DOI: 10.1016/j.brainresbull.2017.07.013

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  9 in total

1.  CaMKIV/CREB/BDNF signaling pathway expression in prefrontal cortex, amygdala, hippocampus and hypothalamus in streptozotocin-induced diabetic mice with anxious-like behavior.

Authors:  Camila Espasandín; Sofía Rivero; Laura Bengoa; Karina Cal; Gerardo Romanelli; Juan Claudio Benech; Juan Pablo Damián
Journal:  Exp Brain Res       Date:  2022-08-19       Impact factor: 2.064

2.  Wenyang Jieyu Decoction Alleviates Depressive Behavior in the Rat Model of Depression via Regulation of the Intestinal Microbiota.

Authors:  Zhenyu Feng; Xiaojuan Ma; Shuang Meng; Hongjuan Wang; Xiaorong Zhou; Min Shi; Jie Zhao
Journal:  Evid Based Complement Alternat Med       Date:  2020-07-23       Impact factor: 2.629

3.  The antioxidant gallic acid induces anxiolytic-, but not antidepressant-like effect, in streptozotocin-induced diabetes.

Authors:  Mariana Machado Pereira; Helen de Morais; Eldevan Dos Santos Silva; Claudia Rita Corso; Eliana Rezende Adami; Rose Maria Carlos; Alexandra Acco; Janaina Menezes Zanoveli
Journal:  Metab Brain Dis       Date:  2018-06-23       Impact factor: 3.584

4.  Melatonin ameliorates cognitive memory by regulation of cAMP-response element-binding protein expression and the anti-inflammatory response in a rat model of post-traumatic stress disorder.

Authors:  Bombi Lee; Insop Shim; Hyejung Lee; Dae-Hyun Hahm
Journal:  BMC Neurosci       Date:  2018-07-04       Impact factor: 3.288

5.  Fluoxetine regulates eEF2 activity (phosphorylation) via HDAC1 inhibitory mechanism in an LPS-induced mouse model of depression.

Authors:  Weifen Li; Tahir Ali; Chengyou Zheng; Zizhen Liu; Kaiwu He; Fawad Ali Shah; Qingguo Ren; Shafiq Ur Rahman; Ningning Li; Zhi-Jian Yu; Shupeng Li
Journal:  J Neuroinflammation       Date:  2021-02-01       Impact factor: 8.322

6.  The Influence of CYP2D6 and CYP2C19 Genetic Variation on Diabetes Mellitus Risk in People Taking Antidepressants and Antipsychotics.

Authors:  Isabelle Austin-Zimmerman; Marta Wronska; Baihan Wang; Haritz Irizar; Johan H Thygesen; Anjali Bhat; Spiros Denaxas; Ghazaleh Fatemifar; Chris Finan; Jasmine Harju-Seppänen; Olga Giannakopoulou; Karoline Kuchenbaecker; Eirini Zartaloudi; Andrew McQuillin; Elvira Bramon
Journal:  Genes (Basel)       Date:  2021-11-03       Impact factor: 4.096

7.  Efficacy of Lycium barbarum polysaccharide in adolescents with subthreshold depression: interim analysis of a randomized controlled study.

Authors:  Xiaoyue Li; Xuan Mo; Tao Liu; Robin Shao; Kayla Teopiz; Roger S McIntyre; Kwok-Fai So; Kangguang Lin
Journal:  Neural Regen Res       Date:  2022-07       Impact factor: 5.135

8.  Centrally Administered Cortistation-14 Induces Antidepressant-Like Effects in Mice via Mediating Ghrelin and GABAA Receptor Signaling Pathway.

Authors:  JinHong Jiang; YaLi Peng; XueYa Liang; Shu Li; Xin Chang; LongFei Li; Min Chang
Journal:  Front Pharmacol       Date:  2018-07-19       Impact factor: 5.810

Review 9.  The Role of Oxidative Stress in Common Risk Factors and Mechanisms of Cardio-Cerebrovascular Ischemia and Depression.

Authors:  Danfeng Lin; Lingling Wang; Shenqiang Yan; Qing Zhang; John H Zhang; Anwen Shao
Journal:  Oxid Med Cell Longev       Date:  2019-11-15       Impact factor: 6.543

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.